Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

R 21

Next Previous
Drug Profile

R 21

Alternative Names: Malaria virus-like particle vaccine - MultiMalVax; Matrix-M; Plasmodium falciparum circumsporozoite protein/HBsAg subunit vaccine - Multimalvax; R21

Latest Information Update: 28 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Oxford
  • Developer GlaxoSmithKline; University of Oxford
  • Class Antimalarials; Parasitic vaccines; Subunit vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Falciparum malaria

Most Recent Events

  • 28 Oct 2019 No recent reports of development identified for phase-I development in Falciparum-malaria(Prevention) in Burkina Faso (IM, Injection)
  • 06 Sep 2019 University of Oxford and Kenya Medical Research Institute plan a phase IIb trial for Falciparum malaria (Prevention, Combination therapy) in Kenya (IM, Injection), in January 2020 , (NCT03947190)
  • 01 Apr 2019 University of Oxford plans a phase Ib/IIb trial for Falciparum malaria (Prevention, In infants) in Burkina Faso, in May 2019 (NCT03896724)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top